← State exam

78. Pancreatic endocrine tumours

High yield

Neuroendocrine tumours of the islets; insulinoma and gastrinoma lead the functioning types; most are non-functioning and resected.

Exam Prep · State examSurgery · HPBSurgery · Surgical oncology

1. Definition

  • Pancreatic neuroendocrine tumours (PNETs, pNENs) → tumours from the endocrine (islet) cells of the pancreas
  • Functioning → release a hormone and cause a clinical syndrome (insulinoma, gastrinoma, glucagonoma, VIPoma, somatostatinoma)
  • Non-functioning → no hormone syndrome (may release chromogranin A or pancreatic polypeptide)
  • Neuroendocrine carcinoma (NEC) → poorly differentiated, high-grade, aggressive

2. Epidemiology

  • About 1–2% of pancreatic tumours; incidence rising (about 1 per 100,000 a year), mainly from incidental small tumours on imaging
  • Non-functioning → 60–90%; most common type today
  • Insulinoma → most common functioning PNET (1–4 per million a year); women slightly more; age 40–60
  • Gastrinoma → second most common functioning; in the pancreas or duodenum (duodenum in up to 60–70%)
  • Glucagonoma, VIPoma, somatostatinoma → rare
  • 5–15% hereditary → MEN1, von Hippel-Lindau (VHL), neurofibromatosis type 1, tuberous sclerosis
  • Better prognosis than adenocarcinoma → 5-year survival about 50–60% across all stages; over 90% for small localised tumours

3. Aetiology and risk factors

  • Most sporadic
  • Genetic syndromes:
    • MEN1 (menin gene, chromosome 11) → "3 Ps": parathyroid (hyperparathyroidism, 90%), pancreas (PNETs: non-functioning, gastrinoma, insulinoma), pituitary (prolactinoma)
    • VHL → non-functioning PNETs, serous cystadenomas, phaeochromocytoma, renal cell carcinoma, haemangioblastomas
    • NF1 → duodenal somatostatinoma
    • Tuberous sclerosis
  • Somatic mutations → MEN1, DAXX/ATRX, mTOR pathway genes
  • Weak links → family history of cancer, smoking, diabetes

4. Pathogenesis

  • From islet or ductal stem cells with neuroendocrine features
  • Insulinoma → insulin release not controlled by glucose → fasting hypoglycaemia; over 90% benign, small (under 2 cm), single, spread evenly through the gland
  • Gastrinoma → gastrin excess → acid hypersecretion → Zollinger-Ellison syndrome (multiple, severe, atypical ulcers; diarrhoea from acid inactivating lipase); 60–90% malignant; most in the gastrinoma triangle
  • Glucagonoma → glucagon → catabolism, diabetes, necrolytic migratory erythema; mostly malignant, body and tail
  • VIPoma (Verner-Morrison) → vasoactive intestinal peptide → watery diarrhoea, hypokalaemia, achlorhydria (WDHA); mostly malignant
  • Somatostatinoma → inhibits many hormones → diabetes, gallstones, steatorrhoea
  • Non-functioning → found late (larger), mass effect, liver metastases
  • Spread → lymph nodes, liver (most common), bone
  • Malignancy → defined by spread or invasion, not cell appearance; risk rises with size (over 2 cm), grade and Ki-67

5. Classification

WHO 2019 grade (well-differentiated NETs)

  • G1 → Ki-67 under 3%, mitoses under 2 per 2 mm²
  • G2 → Ki-67 3–20%, mitoses 2–20
  • G3 → Ki-67 over 20%, well differentiated
  • NEC → poorly differentiated, Ki-67 over 20% (small cell or large cell)
  • MiNEN → mixed neuroendocrine and non-neuroendocrine

Gastrinoma triangle (Passaro)

  • Junction of the cystic and common bile ducts (above)
  • Junction of the second and third parts of the duodenum (below)
  • Junction of the neck and body of the pancreas (medial)
  • Contains about 80–90% of gastrinomas

Functioning tumours

  • Insulinoma → insulin
  • Gastrinoma → gastrin
  • Glucagonoma → glucagon
  • VIPoma → VIP
  • Somatostatinoma → somatostatin
  • Rare → ACTHoma, PTHrP-oma, serotonin-producing
Table of functioning pancreatic neuroendocrine tumours
Diagram: functioning pancreatic endocrine tumours, their syndromes and tests

6. Clinical picture

Symptoms

  • Insulinoma → Whipple's triad:
    1. Symptoms of hypoglycaemia on fasting or exercise
    2. Low blood glucose at the time (under 2.2–3.0 mmol/L)
    3. Relief with glucose
    4. Neuroglycopenic → confusion, odd behaviour, visual disturbance, seizures, coma (often misdiagnosed as epilepsy or psychiatric illness)
    5. Adrenergic → sweating, tremor, palpitations, hunger
    6. Weight gain (eating to prevent attacks)
  • Gastrinoma (Zollinger-Ellison):
    • Recurrent, refractory peptic ulcers, often multiple, in unusual sites (jejunum, distal duodenum), recurrence after surgery
    • Diarrhoea (secretory, improves with PPI), steatorrhoea
    • Reflux oesophagitis, complications (bleeding, perforation)
  • Glucagonoma → necrolytic migratory erythema (red, blistering, crusting rash in the groin, buttocks, face), diabetes, weight loss, DVT, glossitis, depression ("4 Ds": dermatitis, diabetes, DVT, depression)
  • VIPoma → profuse watery diarrhoea (over 3 L a day, "pancreatic cholera"), hypokalaemia, dehydration, flushing
  • Somatostatinoma → diabetes, gallstones, steatorrhoea, weight loss
  • Non-functioning → incidental; epigastric pain, weight loss, jaundice, mass, liver metastases

Signs

  • Often none
  • Rash (glucagonoma), dehydration (VIPoma)
  • Jaundice, mass, hepatomegaly (advanced)
  • MEN1 → signs of hyperparathyroidism (kidney stones, bone pain), pituitary tumour

7. Diagnosis

Biochemistry

  • Insulinoma:
    • Supervised 72-hour fast → gold standard: glucose under 3.0 mmol/L (55 mg/dL) with inappropriately high insulin (≥ 3 µU/mL), C-peptide (≥ 0.6 ng/mL) and proinsulin; low beta-hydroxybutyrate
    • Sulfonylurea screen negative (excludes factitious hypoglycaemia)
    • Factitious insulin injection → high insulin, low C-peptide
  • Gastrinoma:
    • Fasting serum gastrin → over 10 times normal (over 1,000 pg/mL) with gastric pH under 2 is diagnostic
    • Stop PPIs before testing if safe (PPIs raise gastrin)
    • Secretin stimulation test → paradoxical rise in gastrin over 120 pg/mL
    • Basal acid output
  • Glucagonoma → plasma glucagon over 500 pg/mL
  • VIPoma → plasma VIP; low potassium
  • Somatostatinoma → plasma somatostatin
  • Chromogranin A → general tumour marker (false high with PPIs, renal failure)
  • MEN1 screening → calcium, PTH, prolactin; genetic testing in young patients, multiple tumours, or gastrinoma

Localisation

  • Multiphase CT → hypervascular, arterial enhancing lesion; liver metastases
  • MRI (diffusion) → small tumours, liver metastases
  • EUS → most sensitive for small pancreatic tumours (over 90%); FNA for grade (Ki-67); tattoo for surgery
  • Gallium-68 DOTATATE PET-CT (somatostatin receptor imaging) → most sensitive for well-differentiated NETs and metastases; selects patients for PRRT
    • Insulinomas often have few somatostatin receptors → GLP-1 receptor imaging (exendin PET)
  • FDG PET → high-grade tumours
  • Selective arterial calcium stimulation test with hepatic venous sampling → occult insulinoma
  • Intraoperative ultrasound and palpation → finds most remaining tumours; duodenotomy finds small duodenal gastrinomas

8. Differential diagnosis

  • Hypoglycaemia → factitious (insulin, sulfonylureas), adrenal insufficiency, liver failure, alcohol, non-islet cell tumour hypoglycaemia (IGF-2), nesidioblastosis (after gastric bypass), dumping
  • Raised gastrin → PPI use (most common), atrophic gastritis, pernicious anaemia, renal failure, H. pylori, gastric outlet obstruction, retained antrum
  • Diarrhoea → carcinoid syndrome, laxative abuse, inflammatory bowel disease, medullary thyroid cancer
  • Pancreatic mass → ductal adenocarcinoma (hypovascular), solid pseudopapillary neoplasm, metastases (renal cell carcinoma, also hypervascular), accessory spleen

9. Treatment

Conservative

  • Symptom control first:
    • Insulinoma → frequent small meals, diazoxide (inhibits insulin release), somatostatin analogues (care: may worsen hypoglycaemia), glucose infusion
    • Gastrinoma → high-dose PPI (e.g. omeprazole 60–120 mg daily); controls acid in almost all
    • VIPoma → IV fluids and potassium, octreotide
    • Glucagonoma → octreotide, amino acid infusions, zinc, anticoagulation
  • Small non-functioning tumours under 2 cm, G1, asymptomatic → surveillance (MRI or EUS every 6–12 months) is safe, especially in MEN1 and older patients
  • Advanced or metastatic well-differentiated disease:
    • Somatostatin analogues (octreotide, lanreotide) → control symptoms and slow growth (CLARINET)
    • Peptide receptor radionuclide therapy (PRRT) → lutetium-177 DOTATATE for somatostatin receptor-positive tumours
    • Everolimus (mTOR inhibitor), sunitinib (tyrosine kinase inhibitor)
    • Chemotherapy → capecitabine with temozolomide (CAPTEM), streptozocin with 5-FU
  • Liver metastases → TACE, TARE, ablation
  • NEC → platinum-etoposide chemotherapy (like small cell lung cancer); surgery rarely

Surgical

  • Resection is the only cure for localised disease
  • Insulinoma:
    • Enucleation → small, benign, away from the main duct (over 2–3 mm from it); laparoscopic preferred
    • Distal pancreatectomy (spleen-preserving) → body or tail, near the duct
    • Whipple → rarely (deep head tumours)
    • Cure rate over 90%
  • Gastrinoma:
    • Sporadic → exploration with duodenotomy (finds duodenal tumours), intraoperative ultrasound, enucleation or resection with lymphadenectomy (nodes involved often)
    • MEN1 gastrinoma → multiple, small, usually duodenal; surgery debated; resect if over 2 cm; parathyroidectomy first (lowers gastrin and acid)
    • Total gastrectomy → historical (before PPIs)
  • Non-functioning tumours over 2 cm (or growing, G2, symptoms) → formal resection with lymphadenectomy (Whipple or distal pancreatectomy); parenchyma-sparing resections for small low-grade tumours
  • Glucagonoma, VIPoma, somatostatinoma → resection with nodes (most are malignant); debulking for symptoms
  • Liver metastases → resection or debulking (if over 70–90% can be removed) improves symptoms and survival; liver transplantation in very selected patients
  • Cholecystectomy during surgery if long-term somatostatin analogues are planned (gallstones)
Flowchart of the management of pancreatic neuroendocrine tumours
Diagram: pancreatic neuroendocrine tumours, from diagnosis to treatment

10. Complications

  • Disease → hypoglycaemic brain injury, ulcer complications (bleeding, perforation, stricture), dehydration and renal failure (VIPoma), VTE (glucagonoma), liver metastases, carcinoid crisis (rare)
  • Enucleation → pancreatic fistula (higher than with formal resection, up to 30–40%)
  • Resection → fistula, delayed gastric emptying, diabetes, exocrine insufficiency
  • PPIs → B12 deficiency, fractures, C. difficile infection
  • Somatostatin analogues → gallstones, steatorrhoea, hyperglycaemia
  • PRRT → bone marrow suppression, renal toxicity

Mind map Pinch or scroll to zoom · drag to move

Show as a list

Pancreatic NETs

  • Types
    • Non-functioning: most
    • Insulinoma: commonest functioning
    • Gastrinoma
    • Glucagonoma
    • VIPoma
    • Somatostatinoma
  • Genetics
    • MEN1: 3 Ps
    • VHL
  • Grade
    • Ki-67: G1 < 3, G2 3-20, G3 > 20
    • NEC
  • Insulinoma
    • Whipple's triad
    • 72-hour fast
    • C-peptide
    • Enucleation
  • Gastrinoma
    • Zollinger-Ellison
    • Gastrin, secretin test
    • Triangle
    • Duodenotomy
  • Imaging
    • Arterial enhancing
    • EUS
    • Ga-68 DOTATATE PET
  • Treatment
    • Resect > 2 cm
    • Watch < 2 cm
    • Octreotide, lanreotide
    • PRRT
    • Everolimus

More in State exam